AI Engines For more Details: Perplexity Kagi Labs You
Skin Infections: Bacitracin is effective against a variety of bacteria and is commonly used to prevent or treat skin infections, including:
Wound Healing: Bacitracin can promote wound healing by preventing bacterial infection in minor wounds and cuts. It creates a barrier against bacteria, allowing the skin to heal without interference from pathogens.
Eye Infections: Bacitracin ophthalmic ointment is used to treat bacterial eye infections, such as conjunctivitis (pink eye), keratitis, and blepharitis. It is typically applied to the inner eyelid to prevent bacterial growth and promote healing.
Prevention of Infections: Bacitracin is sometimes applied to surgical incisions or wounds to prevent bacterial infections during the healing process.
Dermatological Conditions: Bacitracin may be used in the treatment of certain dermatological conditions where bacterial infection is a concern, such as eczema, psoriasis, and acne.
Nasal Infections: Bacitracin may be used intranasally to eliminate nasal carriage of Staphylococcus aureus bacteria, particularly in patients at risk for surgical site infections or those with recurrent skin infections.
Secondary Infections: Bacitracin is often included in combination with other antibiotics in topical ointments, creams, or sprays for the treatment of secondary bacterial infections associated with skin conditions or wounds.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium animalis | Reduces |
| species | Bifidobacterium bifidum | Reduces |
| species | Bifidobacterium breve | Reduces |
| species | Bifidobacterium catenulatum | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Bifidobacterium pseudocatenulatum | Reduces |
| species | Bifidobacterium pseudolongum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 1 | -0.67 |
| ADHD | 6.1 | 1 | 5.1 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.5 | 2.6 | 0.35 |
| Allergies | 8.2 | 3.6 | 1.28 |
| Allergy to milk products | 1.5 | 2.2 | -0.47 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.7 | 9.5 | -0.42 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 0.4 | 7.25 |
| Ankylosing spondylitis | 4.5 | 1.5 | 2 |
| Anorexia Nervosa | 3.4 | 3.2 | 0.06 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.3 | 4.33 |
| Asthma | 5.7 | 2.7 | 1.11 |
| Atherosclerosis | 2 | 2.5 | -0.25 |
| Atrial fibrillation | 4.2 | 3.2 | 0.31 |
| Autism | 11.5 | 11 | 0.05 |
| Autoimmune Disease | 1.3 | 1.1 | 0.18 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.4 | 2.4 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 1.5 | 1.5 | 0 |
| Breast Cancer | 0.8 | 0.3 | 1.67 |
| Cancer (General) | 0.6 | 3.1 | -4.17 |
| Carcinoma | 4.7 | 3.2 | 0.47 |
| Celiac Disease | 4.3 | 4.4 | -0.02 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 5.9 | 7.8 | -0.32 |
| Chronic Kidney Disease | 5.2 | 2.9 | 0.79 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 1.7 | 0.29 |
| Chronic Urticaria (Hives) | 1.5 | 1.2 | 0.25 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.3 | 0.08 |
| Cognitive Function | 4.2 | 1.7 | 1.47 |
| Colorectal Cancer | 8.1 | 2.4 | 2.38 |
| Constipation | 2.1 | 1.3 | 0.62 |
| Coronary artery disease | 2.5 | 3 | -0.2 |
| COVID-19 | 10.6 | 14.3 | -0.35 |
| Crohn's Disease | 9.4 | 6.6 | 0.42 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.8 | -1.57 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 13 | 10.4 | 0.25 |
| Dermatomyositis | 0.3 | 0.4 | -0.33 |
| Eczema | 2.1 | 3 | -0.43 |
| Endometriosis | 3.6 | 2.1 | 0.71 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.3 | 1.8 | 0.83 |
| erectile dysfunction | 2.3 | 0.4 | 4.75 |
| Fibromyalgia | 3.8 | 2.7 | 0.41 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 5 | 0.38 |
| gallstone disease (gsd) | 3.9 | 0.9 | 3.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 2.8 | -0.87 |
| Generalized anxiety disorder | 2.6 | 2.5 | 0.04 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 1.9 | 0.11 |
| Graves' disease | 2 | 3.4 | -0.7 |
| Gulf War Syndrome | 1.4 | 1.6 | -0.14 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.7 | 1.9 | 0.95 |
| Heart Failure | 4.3 | 2 | 1.15 |
| hemorrhagic stroke | 2.1 | 2.1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.5 | 1.2 | 0.25 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | |
| hyperglycemia | 1.7 | 1.2 | 0.42 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.8 | 7.5 | -0.56 |
| Hypothyroidism | 1.1 | -1.1 | |
| Hypoxia | 3.2 | 1 | 2.2 |
| IgA nephropathy (IgAN) | 1.6 | 5.4 | -2.38 |
| Inflammatory Bowel Disease | 9.8 | 10.6 | -0.08 |
| Insomnia | 2.5 | 2.4 | 0.04 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 1.2 | 1 | 0.2 |
| Irritable Bowel Syndrome | 8.2 | 5.9 | 0.39 |
| ischemic stroke | 2.8 | 1.7 | 0.65 |
| Liver Cirrhosis | 8.3 | 3.6 | 1.31 |
| Long COVID | 9.2 | 8.5 | 0.08 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1 | 0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 1 | -0.11 |
| ME/CFS with IBS | 1.1 | 2.5 | -1.27 |
| ME/CFS without IBS | 2 | 2.5 | -0.25 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.8 | 0.6 | 2 |
| Metabolic Syndrome | 10.1 | 9.6 | 0.05 |
| Mood Disorders | 13.1 | 10 | 0.31 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 9.1 | 7.1 | 0.28 |
| Multiple system atrophy (MSA) | 1.2 | 1 | 0.2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.7 | -11.33 |
| Neuropathy (all types) | 0.7 | 2.8 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.7 | 5.2 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.7 | 1 |
| Obesity | 12.4 | 10 | 0.24 |
| obsessive-compulsive disorder | 6.5 | 4.9 | 0.33 |
| Osteoarthritis | 3.3 | 1.4 | 1.36 |
| Osteoporosis | 3 | 1.8 | 0.67 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 9.6 | 8.6 | 0.12 |
| Polycystic ovary syndrome | 7.7 | 3.3 | 1.33 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.7 | -2.5 |
| Premenstrual dysphoric disorder | 0.8 | 0.4 | 1 |
| primary biliary cholangitis | 2.3 | 1.4 | 0.64 |
| Primary sclerosing cholangitis | 2.5 | 3.2 | -0.28 |
| Psoriasis | 4 | 3.4 | 0.18 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.5 | 4.5 | 1.11 |
| Rosacea | 1.3 | 1.6 | -0.23 |
| Schizophrenia | 7.1 | 4.3 | 0.65 |
| scoliosis | 0.4 | 1.2 | -2 |
| Sjögren syndrome | 3.3 | 3.1 | 0.06 |
| Sleep Apnea | 2.3 | 1.8 | 0.28 |
| Slow gastric motility / Gastroparesis | 1 | 0.4 | 1.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.5 | 0.5 | 4 |
| Stress / posttraumatic stress disorder | 3.1 | 2.8 | 0.11 |
| Systemic Lupus Erythematosus | 4.6 | 2.6 | 0.77 |
| Tic Disorder | 1.5 | 1.9 | -0.27 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 5.1 | 4.3 | 0.19 |
| Type 2 Diabetes | 11.1 | 8.4 | 0.32 |
| Ulcerative colitis | 8 | 9.1 | -0.14 |
| Unhealthy Ageing | 5.9 | 3 | 0.97 |
| Vitiligo | 2.6 | 1.6 | 0.63 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
